Microvascular disease relevance in the hypertension syndrome

Area of Science:

• Cardiology
• Vascular Biology
• Metabolic Diseases

Background:

• Hypertension frequently co-exists with conditions like smoking, obesity, diabetes, and dyslipidemia.
• These co-morbidities are associated with microvascular disease (MVD), characterized by abnormal PET scans and endothelial dysfunction.
• Microvascular disease (MVD) may contribute to left ventricular hypertrophy (LVH) by disrupting the balance of cellular growth and death signals.

Purpose of the Study:

• To explore the role of microvascular disease (MVD) and apoptosis in hypertension and heart failure.
• To investigate the potential of existing therapies like digitalis in preserving myocyte integrity.
• To propose a paradigm shift in clinical practice for managing heart failure.

Main Methods:

• The study reviews existing literature on hypertension, co-morbidities, MVD, and heart failure.
• It analyzes the mechanisms linking MVD and apoptosis to left ventricular hypertrophy (LVH).
• It discusses the potential anti-apoptotic and MVD-blunting effects of digitalis and other antihypertensive agents.

Main Results:

• Co-morbidities associated with hypertension contribute to MVD and endothelial dysfunction.
• MVD and an imbalance in apoptotic signals may lead to left ventricular hypertrophy (LVH).
• Digitalis and certain antihypertensive drugs show potential in mitigating MVD and apoptosis.

Conclusions:

• Heart failure progression is linked to myocyte deterioration, not just altered contractility.
• Preserving myocyte integrity through anti-apoptotic and MVD-blunting strategies is key.
• Recognizing the roles of apoptosis and MVD could revolutionize heart failure management.